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Background: The very aggressive nature and low survival rate of pancreatic ductal adenocarcinoma (PDAC)
dictates the necessity to find novel efficacious therapies. Recent evidence suggests that phosphoinositide 3-kinase
(PI3K) and 3-phosphoinositide-dependent protein kinase 1 (PDK1) are key effectors of oncogenic KRAS in PDAC.
Herein, we report the role and mechanism of action of PDK1, a protein kinase of the AGC family, in PDAC.
Methods: PDAC cell lines were treated with selective PDK1 inhibitors or transfected with specific PDK1-targeting
siRNAs. In vitro and in vivo assays were performed to investigate the functional role of PDK1 in PDAC. Specifically,
anchorage-dependent and anchorage-independent growth was assessed in PDAC cells upon inhibition or
downregulation of PDK1. Detailed investigation of the effect of PDK1 inhibition/downregulation on specific
signalling pathways was also performed by Western blotting analysis. A xenograft tumour mouse model was used
to determine the effect of pharmacological inhibition of PDK1 on PDAC cells growth in vivo.
Results: Treatment with specific inhibitors of PDK1 impaired anchorage-dependent and anchorage-independent
growth of pancreatic cancer cell lines, as well as pancreatic tumour growth in a xenograft model. Mechanistically,
inhibition or downregulation of PDK1 resulted in reduced activation of the serum/glucocorticoid regulated
kinase family member 3 and subsequent reduced phosphorylation of its target N-Myc downstream regulated 1.
Additionally, we found that combination of sub-optimal concentrations of inhibitors selective for PDK1 and the
class IB PI3K isoform p110γ inhibits pancreatic cancer cell growth and colonies formation more potently than each
single treatment.
Conclusions: Our data indicate that PDK1 is a suitable target for therapeutic intervention in PDAC and support the
clinical development of PDK1 inhibitors for PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is amongst
the five most deadly human malignancies, having a© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
* Correspondence: marco.falasca@curtin.edu.au
†Tania Maffucci and Marco Falasca jointly supervised this work
1Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences,
Curtin Health Innovation Research Institute, Curtin University, Perth, Western
Australia 6102, Australia
2Queen Mary University of London, Barts and The London School of
Medicine and Dentistry, Blizard Institute, Centre for Cell Biology and
Cutaneous Research, E1 2AT, London, UK
Full list of author information is available at the end of the article5-year relative survival rate of ~8% [1]. PDAC is
associated with high-frequency somatic mutations in a
subset of genes, most frequently in the gene encoding
the small GTPase KRAS, which is mutated in the major-
ity of human PDAC (> 95%) [2]. The genes encoding the
tumour suppressor p53, SMAD4 and p16Ink4A are also
frequently mutated in PDAC with many other accessory
mutations also being observed at varied frequency [3].
Since their discovery, phosphoinositide 3-kinases
(PI3Ks) have been established as major signalling mole-
cules implicated in different cellular functions such asle is distributed under the terms of the Creative Commons Attribution 4.0
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vival and angiogenesis. Abnormal PI3K signalling has
been estimated to occur in as many as 50% of all human
malignancies and this pathway is a well-established tar-
get for anti-cancer therapies [4]. The PI3K family com-
prises of eight mammalian isoforms grouped into three
classes. Class IA consists of a catalytic subunit and a
regulatory subunit. The catalytic subunits include p110α,
p110β, or p110δ, while the regulatory subunits consist of
p85α, p85β or p55γ. Class IB consists of only one cata-
lytic subunit, p110γ, and two regulatory subunits, p87
and p101. We previously reported that p110γ is overex-
pressed in human PDAC and plays a key role in pancreatic
cancer cell proliferation [5]. These data were confirmed by
a recent study also reporting increased levels of p110γ in
human pancreatic cancer tissues as well as its role in regu-
lation of pancreatic cancer cell growth [6]. Similarly,
p110γ overexpression was detected in human hepatocellu-
lar carcinoma (HCC) where the enzyme was also shown
to be a key regulator of cellular proliferation [7].
In response to receptor tyrosine kinases or G-protein
coupled receptors activation, class I PI3Ks catalyse the
phosphorylation of the 3′ position of the inositol ring of
phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5) P2]
which leads to the synthesis of the membrane bound
phospholipid phosphatidylinositol 3,4,5-trisphosphate
[PtdIns(3,4,5) P3] [8]. PtdIns(3,4,5) P3 then acts as a
second messenger and regulates both plasma membrane
translocation and activation of several proteins. The
tumour suppressor phosphatase and tensin homolog
(PTEN) inhibits this signalling pathway by dephosphory-
lating PtdIns(3,4,5) P3 back to PtdIns(4,5) P2. The best
characterized PI3K/PtdIns(3,4,5) P3 downstream effector
is the Serine/Threonine-specific protein kinase B (PKB)/
Akt that binds to PtdIns(3,4,5) P3 via its pleckstrin
homology (PH) domain. Once at the plasma membrane,
Akt is phosphorylated at its residue Thr308 by the
3-phosphoinositide-dependent protein kinase 1 (PDK1),
which itself associates to the membrane via PH
domain-dependent binding to PtdIns(3,4,5) P3, and at its
residue Ser473 by other kinases, including the complex
2 of mechanistic target of rapamycin. PDK1 belongs to
the family of AGC kinases and was first discovered in
1997 for its ability to phosphorylate Akt at Thr308.
Although the contribution of PI3K and PI3K-dependent
pathways to cancer development and progression has
been well established for many years, the first major
indication that PDK1 itself might be a viable target in
cancer only appeared in 2005 when Bayascas et al gener-
ated transgenic hypomorphic PDK1 mice [9]. When
these mice were crossed with tumourigenic heterozygous
PTEN+/− mice, the prevalence of tumour development
was reduced in mice with deficient PDK1 levels, con-
firming the importance of PDK1 in tumour developmentdriven by loss of PTEN [9]. Further evidence of a spe-
cific role for PDK1 in cancer is provided by the observa-
tion that increased copy number of PDPK1, the gene
encoding for PDK1, is frequently observed in different
cancer types [10–12]. Evidence is also emerging indicat-
ing that PDK1 inhibition can impact on several cellular
functions associated with cancer progression, such as
reduced invasion on Matrigel of breast, prostate and
melanoma cancer cell lines [13–15]. Similarly, stable
downregulation of PDK1 inhibited migration of the breast
cancer cell line MDA-MB-231 and metastasis formation
upon implantation of cells in immunodeficient mice [16].
PDK1 has also been shown to be implicated in ovarian can-
cer aggressiveness via a short form of the Ron receptor
tyrosine kinase [17], and COLL11A1 [18], whereas its
pharmacological inhibition had been previously found to be
able to enhance the effect of chemotherapeutic drugs in the
ovarian cancer cell line SKOV-3 cells [19]. Furthermore,
PDK1 mRNA is correlated with poor survival rates in un-
treated HCC patients and is the most prominent factor in
the time to recurrence prediction, post-operatively [20].
Whilst PDK1 is most commonly associated with Akt
signalling, it has become increasingly evident that the
role of PDK1 in cancer is not limited to Akt activation.
PDK1 can phosphorylate and activate at least 23 AGC
kinases including S6 Kinase, protein kinase C and
serum-and glucocorticoid-induced protein kinase
(SGK) [21]. The diversity of substrates that can be
activated by PDK1 are of high relevance in cancer sig-
nalling. For instance, the PDK1 substrate serum/
glucocorticoid regulated kinase family member 3
(SGK3) is frequently overexpressed in HCC and its
downregulation reduced both colonies formation and
tumour formation in nude mice [22]. In a subset of
breast cancer cell lines, hyperactivation of PI3K path-
ways was reported to be independent from Akt activa-
tion and it was shown that tumourigenicity of the
cells, as assessed by anchorage-independent growth,
was dependent on PDK1 and SGK3 [23]. This pro-
vided the first evidence to suggest that PDK1 can rep-
resent an Akt-independent molecular target in human
malignancies. It is now well established that PI3K/
PDK1-dependent, Akt-independent signalling path-
ways can contribute to tumourigenesis [24, 25].
A previous study reported that deletion of PDPK1
inhibits KRasG12D- driven PDAC development in a
transgenic mouse model [26], revealing a key role for
PDK1 in PDAC initiation. Whether pharmacological
inhibition of the enzyme can inhibit PDAC progression
remains to be established. Here we determined the effect
of selective PDK1 inhibitors on PDAC growth in vitro
and in vivo. This study identified PDK1 as a novel
potential target to develop new treatment strategies in
pancreatic cancer.
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Cell culture and transfection
HPAF-II, AsPC-1, CFPAC-1 and PANC-1 cells were
obtained from ATCC and grown in complete growth
media (Eagle’s Minimum Essential Medium, RPMI-1640
Medium, Iscove’s Modified Dulbecco’s Medium and
Dulbecco’s Modified Eagle Medium, respectively)
supplemented with 10% FBS (Bovogen Biologicals) and
1X Penicillin-Streptomycin-Glutamine (HyClone) at 37 °
C in a 5% CO2 atmosphere. HPDE cells were kindly pro-
vided by Prof H. Kocher (Queen Mary University of
London) and were cultured in keratinocyte serum-free
medium supplemented with epidermal growth factor
(EGF) and bovine pituitary extract (Life Technologies,
Inc.). hTERT-HPNE cells were obtained from ATCC and
cultured in 75% DMEM without glucose supplemented
with 25% Medium M3 Base (INCELL Corporation LLC),
5% FBS, 10 ng/ml human recombinant EGF, 5.5 mM
D-glucose and 750 ng/ml puromycin. For serum starva-
tion, cells were seeded in a 6-well plate at a density of
3.5 × 106 cells/well and were serum starved for 24 h.
After that, cells were stimulated with media containing
10% FBS for 1 h in the presence or absence of the indi-
cated inhibitors.
Downregulation of PDK1 was obtained using the
following siRNAs from Dharmacon: Sequence 1
ON-TARGETplus Standard GACCAGAGGCCAA-
GAAUUUUU; Sequence 2 ON-TARGETplus Standard
(A4) CAAGAGACCUCGUGGAGAAUU. Downregula-
tion of SGK3 was obtained using the following siR-
NAs from Qiagen: Gene Solution siRNA SI00101003
(SGKL 3) and Gene Solution siRNA SI00287588
(SGKL 6). Cells were transfected using 75 nM of
siRNAs and DharmaFECT 1 and DharmaFECT 2
transfection reagents (Dharmacon) according to man-
ufacturer’s instructions.
Cell viability assay
Effect of the drugs on anchorage-dependent growth was
assessed by trypan blue exclusion assay. Briefly, cells were
seeded in 12-well plates at a density of 5 × 104 cells/well
and treated with different concentrations of drugs for 72 h.
Cells were then trypsinized, complete media was added and
10 μl of cell suspension was mixed with trypan blue dye [1].
The mixture was loaded on a Neubauer chamber and the
number of viable cells per mL was calculated as (number of
viable cells / 4) × 104, corrected for the dilution factor.
Anchorage-independent growth – soft agar assay
In order to assess the long-term effect of the drugs and
the PDK1/SGK3 downregulation on the ability of cells
to form 3D colonies (tumourigenicity), anchorage-
independent growth assays were performed. Six-well
plates were coated with a mixture of 1% noble agar:2XRPMI [1:1(v/v)] (bottom layer). Once the first layer
had solidified, a second layer was added, comprising of
0.6% noble agar: 2XRPMI [1:1(v/v)] containing 10,000
cells and supplemented with the required inhibitor or
corresponding vehicle.
Alternatively, 10,000 cells that had been transfected
with siRNAs were plated. After the second layer had so-
lidified, 1x RPMI was added and plates were kept in a
humidified incubator, at 37 °C in a 5% CO2 atmosphere.
After 5 weeks incubation, colonies were fixed and
stained with Crystal Violet (0.05%), visualized with
ChemiDoc XRS+ System (Bio-Rad) and quantified with
ImageJ software.
Cell lysis and Western blotting analysis
Cells were lysed using cold radioimmunoprecipitation
assay buffer (150 mM sodium chloride, 1.0% NP-40 or
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, 50 mM Tris HCl, pH 8.0) supplemented
with 1X Protease/Phosphatase Inhibitor Cocktail (100X
stock, Cell Signaling Technology). After sonication at 4 °
C, lysates were centrifuged at 10,000 g for 10 mins at 4 °
C. Supernatants were transferred to a 1.5 ml tube and
protein concentrations were determined using the Direct
Detect Assay-Free cards and the Direct Detect Spec-
trometer (Merck Millipore, Darmstadt, Germany). Sam-
ples (35 μg/lane) were separated by SDS-PAGE and
transferred to nitrocellulose membranes. Membranes
were incubated in TBS containing Tween-20 (0.05% v/v)
and supplemented with 3% bovine serum albumin
(TBST -BSA) at room temperature (RT) for 1 h followed
by overnight incubation with primary antibodies at 4 °C.
The following day, membranes were washed with TBST
at RT (3 × 10 mins), and incubated for 1 h at RT with
the appropriate secondary antibody (1:20,000). After
three washes in TBST and one wash in TBS, membranes
were incubated with Clarity Western ECL Blotting Sub-
strates (Bio-Rad) and images were acquired using a Che-
miDoc XRS+ System (Bio-Rad). Primary antibodies used
were: pFoxO1 (Thr24)/FoxO3a (Thr32) (#9464), pAkt
(Thr308) (#4056), pSGK3 (Thr320) (#5642), pNDRG1
(Thr346) (#3217), Akt (#9272), SGK3 (#8156), PDK1
(#3062), NDRG1 (#5196), GAPDH (#5174). All anti-
bodies were purchased from Cell Signaling Technology.
Antibodies were diluted in TBST-BSA (1:1000, apart
from pSGK3, 1:500).
In vivo experiments
Athymic CD-1 nu/nu mice (5–7 weeks old) were pur-
chased from Charles River Laboratories (Calco, LC,
Italy) and maintained under specific pathogen-free con-
ditions with food and water provided ad libitum. The
animals’ health status was monitored daily. Procedures
involving animals and their care were established
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with national and international policies (Autorizzazione
N 484/2016-PR Ministero della Salute). HPAF-II (3.5 ×
106) cells were injected subcutaneously into the right
flank of mice. When xenografts became palpable,
tumour-bearing mice were divided into two groups (n =
7) with mice receiving MP7 (75 mg/kg) or vehicle by
oral gavage (5 days/week) for 3 weeks. For this purpose,
MP7 was administered as a suspension in 0.5% methyl-
cellulose + 0.4% tween 80. Tumour volumes were moni-
tored every week using a caliper and volumes were
calculated using the following formula: tumour volume
= (length* width2)/2. The PDK1 inhibitor MP7 was syn-
thesized as previously reported [27] and characterized as
described in Additional file 1. For in vivo xenograft
curves, p values were determined by Student’s t-test and
considered significant at p < 0.05. All statistical analysis
was performed with GraphPad Prism 5.0 software.Fig. 1 siRNA-mediated PDK1 downregulation inhibits cell proliferation and anc
CFPAC-1 (g-i) cells were transfected with two siRNA sequences specifically targe
with trypan blue exclusion (a,d,g) or plated on soft agar (b,e,h), as specified in
siControl and are means ± SEM of n≥ 3 independent experiments performed i
analysis, and data from cells transfected with each siRNA were compared to dat
efficient PDK1 downregulation are also shown (c,f,i,). GAPDH was used as loadiResults
PDK1 inhibition reduces pancreatic cancer cell growth
in vitro and in vivo
To investigate the specific role of PDK1 in pancreatic
cancer proliferation, PDAC cell lines were transiently
transfected with two siRNAs specifically targeting the
protein, as well as a non-targeting siRNA (“siControl”).
Downregulation of PDK1 expression reduced AsPC-1,
HPAF-II and CFPAC-1 anchorage-dependent (Fig. 1 a,
d, g), and anchorage-independent growth (Fig. 1 b, e, h).
Efficient downregulation of PDK1 was confirmed by
Western blotting (Fig. 1 c, f, i). We next determined the
effect of PDK1 pharmacological inhibition on PDAC cells.
Four malignant (HPAF-II, AsPC-1, CFPAC-1, PANC-1)
and two non-malignant pancreatic epithelial cell lines
(hTERT-HPNE, HPDE) were treated with increasing con-
centrations of selective PDK1 inhibitors. Specifically, cells
were treated with the small molecules GSK2334470 [28]horage-independent growth of PDAC cells. AsPC-1 (a-c), HPAF-II (d-f) and
ting PDK1 or a non-targeting siRNA (siControl) and then manually counted
the Methods. Data are expressed as percentage of cells transfected with
n duplicate. T-test and GraphPad Prism version 6.0 were used for statistical
a from cells transfected with siControl. Representative blots confirming
ng control. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001
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pentakisphosphate (InsP5) derivative 2-O-benzyl-InsP5
(2-O-Bn-InsP5) that we previously reported to target PDK1
selectively [29]. We observed that treatment of all cell lines
with each inhibitor significantly and dose-dependently re-
duced the number of AsPC-1 and HPAF-II cells compared
to control cells treated with vehicle (Fig. 2 a-c). Overall,
non-malignant hTERT-HPNE and HPDE cells appeared toFig. 2 Pharmacological inhibition of PDK1 reduces PDAC cells proliferation
HPNE, HPDE) as well as PDAC cells (AsPC-1, HPAF-II) were treated with incr
and 2-O-Bn-InsP5 (c) for 72 h, and cell viability was assessed. Data are expre
and are means ± SEM of n ≥ 3 independent experiments performed in dup
comparisons test was used for statistical analysis between each treatment
with GraphPad Prism version 6.0. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0be slightly or not sensitive to PDK1 inhibition compared to
PDAC cells, with 2-O-Bn-InsP5 not having any statistically
significant effect on hTERT-HPNE and HPDE cell numbers
at any tested concentrations (Fig. 2 a-c). Similar results
were obtained in CFPAC-1 (Additional file 2: Figure S1a,b)
and PANC-1 (Additional file 2: Figure S2a,b). Moreover,
treatment of AsPC-1 cells with the three inhibitors signifi-
cantly reduced their anchorage-independent growth, asin monolayer culture. Non-malignant epithelial pancreatic cells (hTERT-
easing concentrations of the PDK1 inhibitors GSK2334470 (a), MP7 (b)
ssed as percentage of control cells treated with vehicle alone (DMSO)
licate. For each cell line, one-way ANOVA with Dunnett’s multiple
and its corresponding DMSO-treated control. Analysis was performed
.0001
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Figure S3a). PDK1 inhibition also reduced anchorage-
independent growth in CFPAC-1 (Additional file 2: Figure
S1c,d), PANC-1 (Additional file 2: Figure S2c,d, Additional
file 2: Figure S3b-d), and HPAF-II (Additional file 2: Figure
S4a,b) cells. It has been reported previously that genetic ab-
lation of PDPK1 reduces KRasG12D- driven PDAC develop-
ment in a transgenic mouse model and that treatment with
a pan class I PI3Ks inhibitor reduces PDAC progression in
KPC mice, the animal model that most accurately recapitu-
lates the human disease [26]. Whether pharmacological in-
hibition of PDK1 could also affect progression of PDAC
in vivo has not been previously assessed. To investigate this
possibility, HPAF-II cells (3.5 × 106) were injected subcuta-
neously into the right flank of athymic CD-1 nu/nu mice
(5–7 weeks old) and mice were treated with MP7 (75mg/
kg) or vehicle, once xenografts became palpable. No body
weight loss was observed during treatments, indicating that
MP7 is well tolerated at the dose used for this study.
Tumour volumes were monitored every week with the useFig. 3 Pharmacological inhibition of PDK1 reduces PDAC cells anchorage i
were treated with PDK1 inhibitors and plated on soft agar. After 5 weeks, c
expressed as percentage of control cells treated with DMSO and are mean
One-way ANOVA with Dunnett’s multiple comparisons test was used for st
treated control. Analysis was performed with GraphPad Prism version 6.0. *
were injected with HPAF-II cells and treated as described in the Methods s
times after start of treatment with MP7. * p < 0.05 as assessed by Student’sof a caliper, and volumes were calculated as described in
the Methods section. Treatment of mice with MP7 signifi-
cantly inhibited tumour growth in vivo (Fig. 3d), indicating
that targeting PDK1 pharmacologically is able to reduce
PDAC progression in vivo.
Taken together these data indicate that PDK1 regulates
PDAC cell proliferation and that inhibition of the
enzyme can efficiently reduce PDAC growth in vitro. At
the same time, our in vivo results, together with previ-
ous evidence using genetic approaches, indicate that
PDK1 represents a novel important target to counteract
PDAC progression, and that MP7 might represent a
valuable drug to be used for PDAC treatment.
PDK1 regulates SGK3 activation in PDAC cells
In order to gain further insight into the mechanisms in-
volved in the PDK1-dependent regulation of PDAC cell
growth, we next analysed the effect of PDK1 inhibition
on activation of specific signalling pathways. First, we
observed that treatment of AsPC-1 (Fig. 4 a), CFPAC-1ndependent growth and PDAC cells growth in vivo. (a-c) AsPC-1 cells
olonies were stained and counted using ImageJ software. Data are
s ± SEM of n ≥ 3 independent experiments performed in duplicate.
atistical analysis between each treatment and its corresponding DMSO-
p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (d) Mice (n = 7/group)
ection. Data indicate means ± SEM of tumour volumes at the indicated
t-test
Fig. 4 Effect of PDK1 pharmacological inhibition on signalling pathways in PDAC cell lines. AsPC-1 (a), CFPAC-1 (b) and HPAF-II (c) cells were
serum starved for 24 h and then treated with GSK2334470 (10μΜ) or MP7 (10μΜ) in the presence or absence of FBS for 1h, prior to cell lysis.
Lysates were analysed by Western blotting using the indicated antibodies (details of antibodies are provided in the Methods section). In all blots
GAPDH was used as loading control. Representative blots are shown. Vertical lines indicate membranes derived from the same gel. In (b,c)
membranes incubated with anti-pAkt (Thr308) were stripped and re-incubated with anti-Akt. *, #, $ indicate membranes that derived from the
same gel (therefore only one GAPDH is shown)
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GSK2334470 or MP7 efficiently blocked the FBS-
induced phosphorylation of Akt at its residue Thr308, a
bona fide readout of PDK1 activity, without affecting the
total levels of Akt. Consistent with reduced Akt activa-
tion, inhibition of FBS-mediated FoxO1(Thr24)/Fox-
O3a(Thr32) phosphorylation was also detected in these
cells (Fig. 4 a-c). Since PDK1 has been described to
regulate SGK3 activation [30] we next investigated the
effect of PDK1 inhibition on SGK3 phosphorylation at
its residue Thr320 in PDAC cells. Consistent with data
on Akt Thr308, inhibition of PDK1 also reduced SGK3
phosphorylation (Fig. 4 a-c). To investigate further the
signalling pathways regulated by PDK1/SGK3 in PDAC
cells we next analysed the effect of PDK1 inhibition on
the metastasis suppressor N-Myc downstream regulated
1 (NDRG1) which has been recently identified as a
downstream target of SGK3 [30]. SGK3 has been re-
ported to regulate NDRG1 phosphorylation at its residue
Thr346, which leads to degradation of the protein [30].
A clear inhibition of NDRG1 Thr346 phosphorylation
(both in the absence and in the presence of FBS) was de-
tected in AsPC-1 (Fig. 4a), CFPAC-1 (Fig. 4b) and
HPAF-II (Fig. 4c) cells upon treatment with both PDK1
inhibitors. Increased protein levels of NDRG1 were ob-
served in FBS-stimulated AsPC-1 (Fig. 4a) and CFPAC-1
(Fig. 4b) cells upon treatment with both PDK1 inhibitors
compared to FBS-stimulated, untreated cells. Consistent
with data obtained using the two inhibitors,siRNAs-mediated downregulation of PDK1 also clearly re-
duced SGK3 and NDRG1 phosphorylation in AsPC-1
(Fig. 5a), CFPAC-1 (Fig. 5b) and HPAF-II (Fig. 5c) cells.
Taken together these data indicate that PDK1 regulates
both SGK3 and NDRG1 in PDAC cell lines. Interest-
ingly, we noticed that downregulation of SGK3
efficiently reduced the number of AsPC-1 (Fig. 6a),
CFPAC-1 (Fig. 6b) and HPAF-II (Fig. 6c) cells, suggest-
ing that inhibition of PDK1 can partly affect PDAC cell
proliferation through its effect on SGK3 activation.
Combination of PDK1 and p110γ inhibitors strongly
reduces pancreatic cancer cell growth in vitro
Previous work in our laboratory demonstrated a key role for
the PI3K isoform p110γ in PDAC cell proliferation [5]. Con-
sistent with our previous report, we observed that treatment
of HPAF-II and AsPC-1 cells with the p110δ/γ inhibitor
IPI-145 (Infinity Pharmaceuticals, Inc.) significantly and dose
dependently reduced cell growth (Fig. 7a). Similarly, treat-
ment with the more potent p110δ/γ inhibitor IPI-742 (Infin-
ity Pharmaceuticals, Inc.) reduced cell growth (Fig. 7b) and
colony formation (Fig. 7c) in HPAF-II cells. Reduced cell
growth was also detected in AsPC-1 cells upon treatment
with IPI-742 (Additional file 2: Figure S5a). Importantly, the
detected inhibition was mainly due to the effect of the com-
pound on p110γ as in the same experimental conditions the
specific p110δ inhibitor CAL-101 affected cell numbers only
slightly when used at the highest concentration in HPAF-II
(Fig. 7b) while it did not affect AsPC-1 cells at any of the
Fig. 5 Effect of PDK1 downregulation on signalling pathways in PDAC cell lines. AsPC-1 (a), CFPAC-1 (b) and HPAF-II (c) were transfected with the
indicated siRNAs and lysed 72 h post-transfection. Lysates were then analysed by Western blotting using the indicated antibodies. Representative blots are
shown. In all blots GAPDH was used as loading control. *indicates membranes that derived from the same gel (therefore only one GAPDH is shown)
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ent with a specific role for p110γ, treatment with IPI-549
(Selleckchem), a novel and specific p110γ inhibitor, reduced
anchorage-dependent growth of PDAC cells without affect-
ing the non-malignant pancreatic epithelial cell lines (Add-
itional file 2: Figure S5b). Reduced anchorage-independent
growth was also detected in AsPC-1 (Additional file 2: Fig-
ure S5c, d) and PANC-1 (Additional file 2: Figure S5c) cells
upon treatment with IPI-549. Interestingly, we observed that
combination of IPI-145 with 2-O-Bn-InsP5 (Fig. 7d) or
GSK2334470 (Fig. 7e) used at sub-optimal concentrations
resulted in enhanced reduction of HPAF-II cell numbers.
Consistent with this, combination of GSK2334470 with
IPI-742 (Additional file 2: Figure S6a) reduced numbers of
AsPC-1 cells more potently than each inhibitor used at
sub-optimal concentrations. A similar trend was observed in
AsPC-1 cells upon combination of IPI-549 with
GSK2334470 (Additional file 2: Figure S6b) and in CFPAC-1
cells upon combination of IPI-549 with either GSK2334470
or 2-O-Bn-InsP5 (Additional file 2: Figure S6c). Finally, we
analysed the effect of these combinations on
anchorage-independent growth. Data indicated that treat-
ment with IPI-742 in combination with either GSK2334470
or 2-O-Bn-InsP5 strongly reduced the number of HPAF-II
colonies in soft agar assays, when sub-optimal concentra-
tions of each inhibitor were used (Fig. 7f). A similar trend
was observed in AsPC-1 (Additional file 2: Figure S6d) and
CFPAC-1 (Additional file 2: Figure S6e) cells when
2-O-Bn-InsP5 was combined with IPI-549.Taken together, these data indicate that simultaneous in-
hibition of the PI3K isoform p110γ and PDK1 affects
PDAC cell growth more potently than inhibition of p110γ
or PDK1 alone, indicating that combination of drugs tar-
geting the two proteins can enhance their effect.
Discussion
In this study, we identified PDK1 as a novel potential thera-
peutic target in PDAC. First, our data demonstrated that
downregulation of the protein using either pharmacological
inhibitors or specific siRNAs reduced PDAC cell numbers
and colonies formation in soft agar assays, indicating that
PDK1 plays a central role in regulation of PDAC cell
growth. Our results are consistent with a previous study
reporting that pancreas-specific deletion of PDPK1 reduced
acinar-to-ductal metaplasia, pancreatic intraepithelial neo-
plasia formation and PDAC formation in a KRasG12D-dri-
ven transgenic model [26]. Interestingly, ablation of
PDPK11 did not affect lung tumour formation in
KRasG12D-driven models of non small cell lung carcinoma
[26], suggesting a specific role for the enzyme during PDAC
development. Whether PDK1 might act specifically down-
stream of mutant KRas in the context of pancreatic cancer
remains to be established [31]. In this respect, it is worth
mentioning that all PDAC cell lines used in our study bear
a KRas mutation in G12 [32], possibly providing further
evidence of a specific KRas/PDK1 pathway in PDAC [31].
In an effort to define the mechanisms of PDK1-
mediated regulation of PDAC cell growth, we observed
Fig. 6 siRNA-mediated SGK3 downregulation inhibits PDAC cells growth. AsPC-1 (a), CFPAC-1 (b) and HPAF-II (c) cells were transfected with two
siRNAs specifically targeting SGK3 or a non-targeting siRNA (siControl) and then manually counted with trypan blue exclusion as specified in the
Methods. Data are expressed as percentage of cells transfected with siControl and are means ± SEM of n ≥ 3 independent experiments
performed in duplicate. T-test and GraphPad Prism version 6.0 were used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. (d)
Representative blot confirming efficient SGK3 downregulation in all cell lines. GAPDH was used as loading control
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effector NDRG1 in PDAC cell lines. Furthermore, down-
regulation of SGK3 using selective siRNAs reduced
PDAC cell numbers, strongly suggesting that PDK1
regulates PDAC cell growth through SGK3 activation, at
least partly. These data are consistent with accumulating
evidence indicating that PDK1 can contribute to cancer
through activation of several downstream effectors.
Indeed, while for many years the potential role of this
enzyme in cancer was almost exclusively associated with
its regulatory role on Akt activation, several recent data
have revealed additional roles for PDK1, independently
of Akt activation [24, 25]. For instance, it was reported
that constitutively active Akt was not able to rescue the
reduced anchorage-independent growth or the increased
apoptosis resulting from downregulation of PDK1 in
breast cancer cells MDA-MB-231 [13]. Importantly,
SGK3, that can be regulated through PDK1-dependent
phosphorylation of residue Thr320 within its T-loop, has
been identified as a key regulator of such PI3K/PDK1-de-
pendent, Akt-independent signalling pathways in cancer
[33]. Evidence includes a study demonstrating thatPDK1-mediated SGK3 activation was critical for
anchorage-independent growth in a subset of PIK3CA (the
gene encoding for p110α) mutant breast cancer cell lines
with minimal Akt activation [23]. Similarly, SGK3 was im-
plicated in Akt-independent oncogenic signalling [33]. Our
data strongly suggest that SGK3 is involved in regulation of
PDAC cell growth downstream of PDK1. Whether PDK1
controls PDAC growth solely through SGK3 activation, in
an Akt-independent mechanism, remains to be established.
Our study further demonstrates that pharmacological
inhibition of PDK1, using three distinct chemical com-
pounds, strongly reduced both anchorage-dependent
and anchorage-independent PDAC cell growth in vitro.
Importantly, we also show that chemical inhibition of
PDK1 reduced growth of PDAC cells in vivo.
Several lines of evidence now support the conclusion
that PDK1 is an important potential therapeutic target
in different cancer types and that its inhibition can prove
beneficial to reduce growth of several cancer cell types.
For instance, we reported that inhibition of PDK1 with
2-O-Bn-InsP5 was able to reduce cell numbers in differ-
ent cancer cell lines as well as growth of prostate cancer
Fig. 7 PDK1 inhibitors enhance the effect of p110δ/γ inhibitors on PDAC cell growth. (a,b) HPAF-II and AsPC-1 cells were treated with the indicated
concentrations of the p110δ/γ inhibitor IPI-145 (a). Alternatively, HPAF-II cells were treated with the indicated concentrations of the p110δ/γ inhibitor
IPI-742 or the selective p110δ inhibitor CAL-101 (b). The number of cells was assessed after 72 h. Data are expressed as percentage of cells treated with
vehicle (control) and are means ± SEM of n = 3 independent experiments performed in duplicate. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs
control cells. (c) HPAF-II cells were plated on soft agar and treated with the indicated concentrations of IPI-742. Data are expressed as percentage of
colonies from cells treated with vehicle (control) and are means ± SEM of n = 4 independent experiments performed in duplicate. *p < 0.05, **p < 0.01
vs control. (d, e) HPAF-II cells were treated with IPI-145 (2 μM), 2-O-Bn-InsP5 (10 μM), GSK2334470 (0.1 μM) or the indicated combinations. The number
of cells was assessed after 72 h. Data are expressed as percentage of cells treated with vehicle (control) and are means ± SEM of n = 3 independent
experiments performed in duplicate. **p < 0.01, ***p < 0.001, ****p < 0.0001. (f) HPAF-II cells were plated on soft agar and treated with IPI-742 (1 μM),
2-O-Bn-InsP5 (10 μM), GSK2334470 (0.1 μM) or the indicated combinations. Data are expressed as percentage of colonies from cells treated with vehicle
(control) and are means ± SEM of n = 3 independent experiments performed in duplicate. **p < 0.01, ***p < 0.001
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larly, MP7 reduced soft agar colony formation in a sub-
set of cancer cell lines as well as primary tumour
xenograft lines [34]. Results from our study further sup-
ports the conclusion that PDK1 represents an important
molecular target to develop novel therapeutic
anti-cancer strategies. More importantly, our results in-
dicate that inhibition of PDK1 can represent a useful
strategy to counteract progression of PDAC. As there
are very few treatments available for pancreatic cancer
patients which provide a very limited increase in sur-
vival, these results might represent an important step
towards the identification of novel, much needed, thera-
peutic options for this deadly disease.Finally, we report that inhibition of PDK1 potentiates the
effect of other drugs in PDAC cell lines. We previously
demonstrated that the class IB PI3K isoform p110γ is over-
expressed in PDAC and it has a critical role in PDAC cell
proliferation [5]. Here we show that combination of select-
ive p110γ inhibitors with PDK1-targeting compounds re-
duced anchorage-dependent and independent-growth of
PDAC cells more potently than each treatment alone, when
used at sub-optimal concentrations. It remains to be estab-
lished whether p110γ and PDK1 act on the same or on dis-
tinct signalling cascades to regulate PDAC growth. Indeed,
the enhanced effect of the combined treatment might be
the result of full inhibition of the same signalling pathway,
as opposed to the effect of each compound alone that, used
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only partially. On the other hand, we cannot rule out the
possibility that the combination of the two classes of
inhibitors can overcome mechanisms of resistance and re-
sult in more pronounced inhibition of PDAC cell growth.
In this respect, it is worth mentioning that several lines of
evidence now suggest that PDK1 can have a role in cancer
chemoresistance and that its inhibition can promote che-
mosensitization [35]. Interestingly, SGK3 has been linked
to development of mechanism of resistance to PI3K and
Akt inhibitors [36] therefore it is tempting to speculate that
the additive effect that we detected by using combination
of p110γ and PDK1 inhibitors might be due to inhibition of
potential PDK1/SGK3-mediated intrinsic mechanisms of
resistance to p110γ inhibitors. Additional studies are now
required to ascertain whether combination of p110γ and
PDK1 inhibitors would prove to be more efficient than each
single agent administration in in vivo models of PDAC.
Conclusions
In summary, in this study we demonstrated that inhibition
of PDK1 reduces PDAC cell growth in vitro and in vivo.
These results, together with previous evidence using
genetic ablation of PDPK1, provide a strong rationale to
investigate further the use of PDK1 inhibitors in
PDAC as novel therapeutic strategies for pancreatic
cancer patients. Our data further suggest that com-
bination of PDK1 inhibitors with selective PI3K inhib-
itors might enhance their anti-cancer activity, possibly
by targeting SGK3-dependent resistance mechanisms.
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Additional file 1: Synthetic procedure followed for the synthesis of MP7
and characterization of intermediates. (DOCX 129 kb)
Additional file 2: Figure S1. Effect of pharmacological inhibition of PDK1 on
CFPAC-1 cells. CFPAC-1 cells were treated with different concentrations of PDK1
inhibitors and their effects on cell viability (a, b) and anchorage independent
growth (c, d) were assessed. Data are expressed as percentage of control cells
treated with DMSO and are means ± SEM of n≥ 3 independent experiments
performed in duplicate. Statistical analysis was performed using GraphPad Prism
version 6.0 and one-way ANOVA with Dunnett’s multiple comparisons test.
*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 vs control. Figure S2. Effect of
pharmacological PDK1 inhibition on PANC-1 cells. PANC-1 cells were treated
with different concentrations of PDK1 inhibitors and their effects on cell viability
(a, b) and anchorage independent growth (c, d) were assessed. Data are
expressed as percentage of control cells treated with DMSO and are means
± SEM of n≥ 3 independent experiments performed in duplicate. Statistical
analysis was performed using GraphPad Prism version 6.0 and one-way ANOVA
with Dunnett’s multiple comparisons test. *p< 0.05, **p< 0.01, ***p< 0.001,
****p< 0.0001 vs control. Figure S3. Representative images of 3D colonies of
AsPC-1 and PANC-1 cells treated with PDK1 inhibitors. Images of AsPC-1
colonies treated with different concentrations of GSK2344470 (a) as well as
PANC-1 colonies treated with MP7 (b) and GSK2344470 (c) were acquired
using 4X magnification lens. (d) Images of the 6-well plates of PANC-1 colonies
treated with GSK2344470 (left) and MP7 (right), as visualized by the ChemiDoc
system (BioRad). Figure S4. Effect of pharmacologicalinhibition of PDK1 on
HPAF-II cells anchorage–independent growth. HPAF-II cells were treated with
the indicated concentrations of the PDK1 inhibitors GSK2334470, 2-O-Bn-InsP5(a) and MP7 (b) and their effects on anchorage-independent growth were
determined. Data are expressed as percentage of control cells treated with
DMSO. Data in (a) are means ± SEM of n= 3 independent experiments per-
formed in duplicate. Statistical analysis was performed using GraphPad Prism
version 6.0 and one-way ANOVA with Dunnett’s multiple comparisons test.
*p< 0.05, **p< 0.01. Data in (b) are means of n= 2 independent experiments
performed in duplicate. Figure S5. Effect of p110δ/γ and p110γ inhibition on
PDAC cells. (a,b) AsPC-1 cells were treated with the indicated concentrations of
the p110δ/γ inhibitor IPI-742 or the selective p110δ inhibitor CAL-101 (a). Alter-
natively, PDAC cells AsPC-1 and HPAF-II, together with the two non-malignant
epithelial pancreatic cell lines hTERT-HPNE and HPDE, were treated with increas-
ing concentrations of the selective p110γ inhibitor IPI-549 (b). Cell viability was
assessed after 72 h. Data are expressed as percentage of cells treated with ve-
hicle alone and are means ± SEM of n≥ 3 independent experiments performed
in duplicate. Statistical analysis was performed using GraphPad Prism version 6.0
and one-way ANOVA with Dunnett’s multiple comparisons test. *p < 0.05,
**p< 0.01, ****p< 0.0001 vs control. (c) AsPC-1 and PANC-1 were plated on soft
agar and treated with the indicated concentrations of IPI-549. Data are
expressed as percentage of cells treated with vehicle alone and are means ±
SEM of n≥ 3 independent experiments performed in duplicate. Statistical ana-
lysis was performed using GraphPad Prism version 6.0 and one-way ANOVA
with Dunnett’s multiple comparisons test. *p< 0.05, **p< 0.01, ***p< 0.001,
****p< 0.0001 vs corresponding control. (d) Representative images of the effect
of different concentrations of IPI-549 on AsPC-1 cells colony formation (4X
magnification lens). Figure S6. PDK1 inhibitors enhance the effect of p110δ/γ
inhibitors. (a-c) AsPC-1 (a,b) and CFPAC-1 (c) cells were treated with the indi-
cated inhibitors alone or in combination. Cell viability was assessed after 72 h.
Data are expressed as percentage of cells treated with vehicle alone and are
means ± SEM of n≥ 3 independent experiments performed in duplicate. Statis-
tical analysis was performed using GraphPad Prism version 6.0 and one-way
ANOVA with Dunnett’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p
< 0.001. (d,e) AsPC-1 (d) and CFPAC-1 (e) cells were plated on soft agar and
treated with the indicated inhibitors and their combination. Data are from
n = 2 independent experiments performed in duplicate. (ZIP 2460 kb)
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